Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers

Journal of Infectious Diseases

Volumn 208, Issue 4, 2013, Pages 584-593

  Tseng, Tai Chung ^a,c,g   Liu, Chun Jen ^b,c   Chen, Chi Ling ^c   Yang, Hung Chih ^b,f   Su, Tung Hung ^b,c   Wang, Chia Chi ^a,g   Yang, Wan Ting ^d   Kuo, Stephanie Fang Tzu ^h   Liu, Chen Hua ^b,c   Chen, Pei Jer ^b,c   Chen, Ding Shinn ^b,c   Kao, Jia Horng ^b,c,d,e  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b Division of Gastroenterology   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d Hepatitis Research Center   (Taiwan)

^e Department of Medical Research ^*  (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g TZU CHI UNIVERSITY   (Taiwan)

^h ST VINCENT S HOSPITAL   (Australia)

Author keywords

HBsAg; HBV DNA; HCC; Intermediate viral load; Minimal risk; Viral hepatitis

Indexed keywords

BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TAIWAN; VIRUS LOAD;

EID: 84984585959     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit209     Document Type: Article

References (35)

1. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262:369-70.
2. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003; 46:400-7.
3. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-92.
4. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2:395-403.
5. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86.
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
7. Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141:517-525 e2.
8. Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55:68-76.
9. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142:1140-1149 e3.
10. Tseng TC, Liu CJ, Chen CL, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 2012; 205:54-63.
11. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26:177-82.
12. Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol 2010; 8:535-40.
13. Chan HL. Identifying hepatitis B carriers at low risk for hepatocellular carcinoma. Gastroenterology 2012; 142:1057-60.
14. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6:531-61.
15. European Association For The Study Of The L. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-85.
16. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-2.
17. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-31.
18. Hung CH, Lu SN, Wang JH, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003; 38:153-7.
19. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993; 21:303-8.
20. Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low HBV loads. Hepatology 2013; 57:441-50.
21. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2.
22. Su TH, Hsu CS, Chen CL, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010; 15:1133-9.
23. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41:659-66.
24. Liu SF, Hsieh MH, Hou NJ, et al. Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. Hepatol Int 2010; 4:601-7.
25. Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013; 58:853-60.
26. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12:568-74.
27. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554-9.
28. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134-43.
29. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-87.
30. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5:1462-8.
31. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28:2437-44.
32. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4:439-74.
33. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54:1591-9.
34. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-95.
35. Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles. Hepatology 2013; doi: 10.1002/hep.26385.